The peptide receptor radionuclide therapy (PRRT) market size is projected to be worth US$ 591.83 million in 2023. The market is likely to reach US$ 1,300 million by 2033. The market is further expected to surge at a CAGR of 8.2% during the forecast period 2023 to 2033.
Key Market Trends and Highlights
| Attributes | Key Insights |
|---|---|
| Peptide Receptor Radionuclide Therapy (PRRT) Market Estimated Size in 2023 | US$ 591.83 million |
| Projected Market Value in 2033 | US$ 1300 million |
| Value-based CAGR from 2023 to 2033 | 8.2% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The scope for peptide receptor radionuclide therapy (PRRT) rose at a 7% CAGR between 2018 and 2022. The global market for peptide receptor radionuclide therapy (PRRT) is anticipated to grow at a moderate CAGR of 8.2% over the forecast period 2023 to 2033.
PRRT emerged as a promising treatment option for neuroendocrine tumors, gaining acceptance among healthcare providers and patients. Extensive clinical trials and regulatory approvals paved the way for the broader application of PRRT. Awareness campaigns and educational initiatives increased knowledge about PRRT, leading to greater patient referrals.
The market expanded steadily, with increased investment in research, development, and production of radioligands. The adoption of PRRT was notable in North America, Europe, and select Asia-Pacific countries, reflecting global potential.
The PRRT market is projected to witness exponential growth, driven by expanded indications, improved radioligands, and global market penetration. PRRT will extend its reach to various indications, including prostate cancer, glioblastoma, and more, diversifying its applications. Advancements in diagnostics will enable personalized PRRT, optimizing patient outcomes and minimizing side effects.
Regulatory bodies will streamline approvals, making PRRT more accessible to patients worldwide. Key players will collaborate with research institutions and healthcare organizations to accelerate innovations and ensure comprehensive patient care.
Principal Consultant
The below table showcases revenues in terms of the top 5 leading countries, spearheaded by the United States and the United Kingdom.
Forecast CAGRs from 2023 to 2033
| The United States | 8.1% |
|---|---|
| The United Kingdom | 8% |
| China | 7.9% |
| Japan | 7.8% |
| South Korea | 7.7% |
Recent efforts to broaden insurance coverage for PRRT procedures have significantly increased patient access. This has been a game-changer for those seeking PRRT treatments.
Collaborative initiatives between pharmaceutical companies, academic institutions, and healthcare providers are accelerating the development of innovative radioligands and treatment protocols. This research synergy is propelling PRRT forward. The emergence of specialized outpatient PRRT centers is streamlining the treatment process, reducing hospital stays, and making PRRT more convenient for patients.
A growing trend in patient empowerment and advocacy is fostering awareness and demand for PRRT, influencing healthcare policies and driving investment. The integration of artificial intelligence in treatment planning and dose optimization is enhancing treatment precision and safety, boosting confidence in PRRT.
Beyond neuroendocrine tumors, PRRT is emerging as a viable treatment option for various cancers, such as prostate cancer and glioblastoma. This diversification extends the market's reach and potential.
Advances in diagnostics and genetic profiling are enabling personalized PRRT treatments. Tailoring therapies to individual patient profiles can enhance treatment outcomes and reduce side effects.
The United Kingdom can establish itself as a hub for PRRT clinical trials. Collaborations between research institutions, pharmaceutical companies, and healthcare providers can accelerate innovation and enhance the nation's standing in the field.
With cutting-edge PRRT facilities and expertise, the United Kingdom can attract medical tourists seeking advanced cancer treatments, boosting both healthcare and tourism sectors. Favorable regulatory policies can streamline PRRT approvals, facilitating faster market entry for new radioligands and treatment protocols.
PRRT is becoming more accessible across China, thanks to a growing number of medical institutions offering PRRT treatments. This increased availability is extending the benefits of PRRT to a larger patient population. Chinese researchers and companies are actively developing their radiopharmaceuticals, pushing the boundaries of treatment precision and effectiveness. These novel radioligands are expected to improve patient outcomes significantly. The integration of PRRT with other treatment modalities, such as immunotherapy and targeted therapies, is gaining traction in China. This combination approach aims to enhance the overall effectiveness of cancer treatments.
Chinese healthcare providers are increasingly focusing on delivering personalized care. PRRT treatment plans are being tailored to individual patient profiles, optimizing therapeutic benefits and minimizing side effects. Regulatory authorities in China are streamlining the approval process for PRRT, making it more efficient and accessible to patients. This regulatory support is expected to further boost the growth of the PRRT market in China.
PRRT is gaining traction in Japan due to recent regulatory approvals, indicating a shift toward recognizing its therapeutic value. The increasing incidence of neuroendocrine tumors (NETs) in Japan has created a strong demand for advanced treatment options, with PRRT emerging as a viable choice.
Ongoing clinical trials and research collaborations are expanding the understanding of PRRT's efficacy and safety, further boosting its credibility. Patient advocacy groups are actively promoting awareness and advocating for improved access to PRRT, amplifying its presence.
Japan's robust healthcare infrastructure and advanced medical technology make it well suited for the implementation of PRRT, ensuring quality patient care. International collaborations and knowledge exchange are facilitating the transfer of expertise, contributing to the growth of PRRT expertise in Japan.
South Korea has emerged as a beacon of promise in the domain of peptide receptor radionuclide therapy (PRRT). With a rapidly growing healthcare sector and a strong focus on medical innovation, South Korea is making significant strides in the field of PRRT.
A key factor driving this promise is the country's dedication to research and development. Korean medical institutions and pharmaceutical companies are investing heavily in PRRT, leading to cutting-edge advancements in radioligands, treatment protocols, and patient care. South Korea's robust healthcare infrastructure and well-trained medical professionals provide a solid foundation for PRRT implementation.
The country's commitment to patient-centric care also ensures that PRRT treatments are administered with the highest standards of safety and efficacy. South Korea's collaborative spirit, both within the country and on the global stage, is accelerating progress in PRRT. Partnerships with international research organizations and industry leaders are fostering innovation and expanding treatment options.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Category | CAGR from 2023 to 2033 |
|---|---|
| Therapeutic Radionuclide | 8.3% |
| Pancreatic Neuroendocrine Tumors | 8.7% |
The therapeutic radionuclide segment is poised to dominate the peptide receptor radionuclide therapy (PRRT) market due to its pivotal role in treating various cancers. PRRT relies on radiopharmaceuticals containing therapeutic radionuclides that selectively target cancer cells, offering precision treatment with reduced side effects.
As research continues to yield innovative radionuclide-based therapies and expand their applications beyond neuroendocrine tumors, the therapeutic radionuclide segment gains prominence. This segment aligns with the growing trend of personalized medicine, where tailored treatments using therapeutic radionuclides offer new hope for patients with different types of malignancies, solidifying its dominance in the PRRT market.
The pancreatic neuroendocrine tumors (pNETs) segment is poised to dominate the peptide receptor radionuclide therapy (PRRT) market due to several compelling factors. pNETs are relatively prevalent, and PRRT has shown remarkable efficacy in managing them.
As awareness of PRRT's benefits spreads, healthcare providers are increasingly opting for this targeted therapy for pNETs. ongoing research is continuously improving radioligands and treatment protocols, further enhancing PRRT's effectiveness in addressing these tumors. With a growing patient pool, expanding research initiatives, and strong clinical outcomes, the pNETs segment is positioned to lead the PRRT market in the coming years.
The peptide receptor radionuclide therapy (PRRT) market boasts a competitive landscape with key players vying for prominence. Novartis AG, Advanced Accelerator Applications (a Novartis company), and ITM Solucin GmbH are at the forefront, pioneering precision medicine in the PRRT domain. Their extensive R&D investments and innovative radioligands set them apart. Other notable contributors include AAA Radiopharma, Curium Pharma, and Telix
Pharmaceuticals, all striving to expand their PRRT portfolios. Collaboration with research institutions and strategic partnerships for global outreach are common strategies. As the PRRT market continues to evolve, competition remains fierce, with a focus on advancing patient care and treatment outcomes.
Recent Developments
| Attribute | Details |
|---|---|
| Estimated Market Size in 2023 | US$ 591.83 million |
| Projected Market Valuation in 2033 | US$ 1,300 million |
| Value-based CAGR 2023 to 2033 | 8.2% |
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Market Analysis | Value in US$ billion |
| Key Regions Covered |
|
| Key Market Segments Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
The peptide receptor radionuclide therapy (PRRT) market is expected to reach at US$ 591.83 million in 2023.
The market for peptide receptor radionuclide therapy (PRRT) is set to expand by a CAGR of 8.2% by 2033.
The peptide receptor radionuclide therapy (PRRT) industry is forecast to reach US$ 1300 million by 2033.
The United States is likely to be the top performing market, surging at a CAGR of 8.1% through 2033.
Therapeutic radionuclide is the preferred segment, expected to rise at an 8.3% CAGR through 2033.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Component 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Component, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Component, 2023 to 2033 5.3.1. Regulatory Peptide 5.3.2. Peptide Analogs 5.3.3. Pharmacokinetic Modifier 5.3.4. Bifunctional Chelating Agents 5.3.5. Therapeutic Radionucleotide 5.4. Y-o-Y Growth Trend Analysis By Component, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Component, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Indication, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication, 2023 to 2033 6.3.1. Gastrointestinal Neuroendocrine Tumours 6.3.2. Lung Neuroendocrine Tumours 6.3.3. Pancreatic Neuroendocrine Tumours 6.3.4. Medullary Carcinoma 6.3.5. Other Indications 6.4. Y-o-Y Growth Trend Analysis By Indication, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Indication, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis by Treatment, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast by Treatment, 2023 to 2033 7.3.1. 3 Therapy Cycles 7.3.2. 4 Therapy Cycles 7.3.3. 5 Therapy Cycles 7.4. Y-o-Y Growth Trend Analysis by Treatment, 2018 to 2022 7.5. Absolute $ Opportunity Analysis by Treatment, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Users 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ Million) Analysis By End Users, 2018 to 2022 8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End Users, 2023 to 2033 8.3.1. Cancer Centres 8.3.2. Home Care Settings 8.3.3. Others 8.4. Y-o-Y Growth Trend Analysis By End Users, 2018 to 2022 8.5. Absolute $ Opportunity Analysis By End Users, 2023 to 2033 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 9.1. Introduction 9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 9.3.1. North America 9.3.2. Latin America 9.3.3. Western Europe 9.3.4. Eastern Europe 9.3.5. South Asia and Pacific 9.3.6. East Asia 9.3.7. Middle East and Africa 9.4. Market Attractiveness Analysis By Region 10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. The USA 10.2.1.2. Canada 10.2.2. By Component 10.2.3. By Indication 10.2.4. By Treatment 10.2.5. By End Users 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Component 10.3.3. By Indication 10.3.4. By Treatment 10.3.5. By End Users 10.4. Key Takeaways 11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Brazil 11.2.1.2. Mexico 11.2.1.3. Rest of Latin America 11.2.2. By Component 11.2.3. By Indication 11.2.4. By Treatment 11.2.5. By End Users 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Component 11.3.3. By Indication 11.3.4. By Treatment 11.3.5. By End Users 11.4. Key Takeaways 12. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Germany 12.2.1.2. United Kingdom 12.2.1.3. France 12.2.1.4. Spain 12.2.1.5. Italy 12.2.1.6. Rest of Western Europe 12.2.2. By Component 12.2.3. By Indication 12.2.4. By Treatment 12.2.5. By End Users 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Component 12.3.3. By Indication 12.3.4. By Treatment 12.3.5. By End Users 12.4. Key Takeaways 13. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. Poland 13.2.1.2. Russia 13.2.1.3. Czech Republic 13.2.1.4. Romania 13.2.1.5. Rest of Eastern Europe 13.2.2. By Component 13.2.3. By Indication 13.2.4. By Treatment 13.2.5. By End Users 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Component 13.3.3. By Indication 13.3.4. By Treatment 13.3.5. By End Users 13.4. Key Takeaways 14. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. India 14.2.1.2. Bangladesh 14.2.1.3. Australia 14.2.1.4. New Zealand 14.2.1.5. Rest of South Asia and Pacific 14.2.2. By Component 14.2.3. By Indication 14.2.4. By Treatment 14.2.5. By End Users 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Component 14.3.3. By Indication 14.3.4. By Treatment 14.3.5. By End Users 14.4. Key Takeaways 15. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. China 15.2.1.2. Japan 15.2.1.3. South Korea 15.2.2. By Component 15.2.3. By Indication 15.2.4. By Treatment 15.2.5. By End Users 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Component 15.3.3. By Indication 15.3.4. By Treatment 15.3.5. By End Users 15.4. Key Takeaways 16. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 16.2.1. By Country 16.2.1.1. GCC Countries 16.2.1.2. South Africa 16.2.1.3. Israel 16.2.1.4. Rest of MEA 16.2.2. By Component 16.2.3. By Indication 16.2.4. By Treatment 16.2.5. By End Users 16.3. Market Attractiveness Analysis 16.3.1. By Country 16.3.2. By Component 16.3.3. By Indication 16.3.4. By Treatment 16.3.5. By End Users 16.4. Key Takeaways 17. Key Countries Market Analysis 17.1. USA 17.1.1. Pricing Analysis 17.1.2. Market Share Analysis, 2022 17.1.2.1. By Component 17.1.2.2. By Indication 17.1.2.3. By Treatment 17.1.2.4. By End Users 17.2. Canada 17.2.1. Pricing Analysis 17.2.2. Market Share Analysis, 2022 17.2.2.1. By Component 17.2.2.2. By Indication 17.2.2.3. By Treatment 17.2.2.4. By End Users 17.3. Brazil 17.3.1. Pricing Analysis 17.3.2. Market Share Analysis, 2022 17.3.2.1. By Component 17.3.2.2. By Indication 17.3.2.3. By Treatment 17.3.2.4. By End Users 17.4. Mexico 17.4.1. Pricing Analysis 17.4.2. Market Share Analysis, 2022 17.4.2.1. By Component 17.4.2.2. By Indication 17.4.2.3. By Treatment 17.4.2.4. By End Users 17.5. Germany 17.5.1. Pricing Analysis 17.5.2. Market Share Analysis, 2022 17.5.2.1. By Component 17.5.2.2. By Indication 17.5.2.3. By Treatment 17.5.2.4. By End Users 17.6. United Kingdom 17.6.1. Pricing Analysis 17.6.2. Market Share Analysis, 2022 17.6.2.1. By Component 17.6.2.2. By Indication 17.6.2.3. By Treatment 17.6.2.4. By End Users 17.7. France 17.7.1. Pricing Analysis 17.7.2. Market Share Analysis, 2022 17.7.2.1. By Component 17.7.2.2. By Indication 17.7.2.3. By Treatment 17.7.2.4. By End Users 17.8. Spain 17.8.1. Pricing Analysis 17.8.2. Market Share Analysis, 2022 17.8.2.1. By Component 17.8.2.2. By Indication 17.8.2.3. By Treatment 17.8.2.4. By End Users 17.9. Italy 17.9.1. Pricing Analysis 17.9.2. Market Share Analysis, 2022 17.9.2.1. By Component 17.9.2.2. By Indication 17.9.2.3. By Treatment 17.9.2.4. By End Users 17.10. Poland 17.10.1. Pricing Analysis 17.10.2. Market Share Analysis, 2022 17.10.2.1. By Component 17.10.2.2. By Indication 17.10.2.3. By Treatment 17.10.2.4. By End Users 17.11. Russia 17.11.1. Pricing Analysis 17.11.2. Market Share Analysis, 2022 17.11.2.1. By Component 17.11.2.2. By Indication 17.11.2.3. By Treatment 17.11.2.4. By End Users 17.12. Czech Republic 17.12.1. Pricing Analysis 17.12.2. Market Share Analysis, 2022 17.12.2.1. By Component 17.12.2.2. By Indication 17.12.2.3. By Treatment 17.12.2.4. By End Users 17.13. Romania 17.13.1. Pricing Analysis 17.13.2. Market Share Analysis, 2022 17.13.2.1. By Component 17.13.2.2. By Indication 17.13.2.3. By Treatment 17.13.2.4. By End Users 17.14. India 17.14.1. Pricing Analysis 17.14.2. Market Share Analysis, 2022 17.14.2.1. By Component 17.14.2.2. By Indication 17.14.2.3. By Treatment 17.14.2.4. By End Users 17.15. Bangladesh 17.15.1. Pricing Analysis 17.15.2. Market Share Analysis, 2022 17.15.2.1. By Component 17.15.2.2. By Indication 17.15.2.3. By Treatment 17.15.2.4. By End Users 17.16. Australia 17.16.1. Pricing Analysis 17.16.2. Market Share Analysis, 2022 17.16.2.1. By Component 17.16.2.2. By Indication 17.16.2.3. By Treatment 17.16.2.4. By End Users 17.17. New Zealand 17.17.1. Pricing Analysis 17.17.2. Market Share Analysis, 2022 17.17.2.1. By Component 17.17.2.2. By Indication 17.17.2.3. By Treatment 17.17.2.4. By End Users 17.18. China 17.18.1. Pricing Analysis 17.18.2. Market Share Analysis, 2022 17.18.2.1. By Component 17.18.2.2. By Indication 17.18.2.3. By Treatment 17.18.2.4. By End Users 17.19. Japan 17.19.1. Pricing Analysis 17.19.2. Market Share Analysis, 2022 17.19.2.1. By Component 17.19.2.2. By Indication 17.19.2.3. By Treatment 17.19.2.4. By End Users 17.20. South Korea 17.20.1. Pricing Analysis 17.20.2. Market Share Analysis, 2022 17.20.2.1. By Component 17.20.2.2. By Indication 17.20.2.3. By Treatment 17.20.2.4. By End Users 17.21. GCC Countries 17.21.1. Pricing Analysis 17.21.2. Market Share Analysis, 2022 17.21.2.1. By Component 17.21.2.2. By Indication 17.21.2.3. By Treatment 17.21.2.4. By End Users 17.22. South Africa 17.22.1. Pricing Analysis 17.22.2. Market Share Analysis, 2022 17.22.2.1. By Component 17.22.2.2. By Indication 17.22.2.3. By Treatment 17.22.2.4. By End Users 17.23. Israel 17.23.1. Pricing Analysis 17.23.2. Market Share Analysis, 2022 17.23.2.1. By Component 17.23.2.2. By Indication 17.23.2.3. By Treatment 17.23.2.4. By End Users 18. Market Structure Analysis 18.1. Competition Dashboard 18.2. Competition Benchmarking 18.3. Market Share Analysis of Top Players 18.3.1. By Regional 18.3.2. By Component 18.3.3. By Indication 18.3.4. By Treatment 18.3.5. By End Users 19. Competition Analysis 19.1. Competition Deep Dive 19.1.1. Advanced Accelerator Applications (AAA) 19.1.1.1. Overview 19.1.1.2. Product Portfolio 19.1.1.3. Profitability by Market Segments 19.1.1.4. Sales Footprint 19.1.1.5. Strategy Overview 19.1.1.5.1. Marketing Strategy 19.1.2. Novartis AG 19.1.2.1. Overview 19.1.2.2. Product Portfolio 19.1.2.3. Profitability by Market Segments 19.1.2.4. Sales Footprint 19.1.2.5. Strategy Overview 19.1.2.5.1. Marketing Strategy 19.1.3. ITM Solucin GmbH 19.1.3.1. Overview 19.1.3.2. Product Portfolio 19.1.3.3. Profitability by Market Segments 19.1.3.4. Sales Footprint 19.1.3.5. Strategy Overview 19.1.3.5.1. Marketing Strategy 19.1.4. National Institutes of Health 19.1.4.1. Overview 19.1.4.2. Product Portfolio 19.1.4.3. Profitability by Market Segments 19.1.4.4. Sales Footprint 19.1.4.5. Strategy Overview 19.1.4.5.1. Marketing Strategy 19.1.5. Australasian Gastro-Intestinal Trials Group 19.1.5.1. Overview 19.1.5.2. Product Portfolio 19.1.5.3. Profitability by Market Segments 19.1.5.4. Sales Footprint 19.1.5.5. Strategy Overview 19.1.5.5.1. Marketing Strategy 20. Assumptions & Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Peptide Receptor Radionuclide Therapy (PRRT) Market
